Latest Blog Posts Tagged "Trophic Factors"
December 20, 2016
Herantis Pharma was awarded a $6M grant to study the safety and efficacy of a potential therapy for Parkinson's disease (PD): cerebral dopamine neurotrophic factor (CDNF).
November 26, 2013
The Michael J. Fox Foundation Contributing Editor Dave Iverson speaks with Kalpana Merchant, PhD of Eli Lilly and Company about the latest in Parkinson's disease research.
November 04, 2013
GDNF is one of a family of proteins called trophic factors that contribute to brain cell growth and survival.
May 21, 2013
In April, we reported on disappointing clinical trial results of Ceregene's trophic factor therapy CERE-120. Today, additional data is announced that could be instructional moving forward.
May 08, 2013
Check out this special breaking news Hot Topics Webinar: "The Future of Trophic Factors," which addresses recent clinical trial results from Ceregene and their therapy CERE-120.
April 26, 2013
Dave Iverson reports on recent disappointing clinical trial results of Ceregene's trophic factor therapy CERE-120.
April 25, 2013
Sign up for a breaking news Webinar (May 1 at noon ET) that will address recent clinical study results from the San Diego-based biotech Ceregene.
April 19, 2013
Ceregene today announced disappointing results from its second Phase 2 trial of CERE-120, an experimental gene therapy treatment for PD. The drug's future development is unclear.
July 20, 2012
According to a report in today's New York Times, the European Medicines Agency has recommended that gene therapy be approved for use in a rare disease called lipoprotein lipase deficiency.
Ceregene: Early Indications that Trophic Factor Biochemically Active in Brain Long After Gene Therapy; More Research Needed
June 05, 2012
Biotech company Ceregene announced evidence of increased levels of the trophic factor neurturin in the brain, for four-plus years following CERE-120 gene therapy to treat Parkinson's disease.